<>
Researchers at the University of South Florida (USF) Health have identified a potential therapeutic pathway for mitigating heart disease in patients with Duchenne muscular dystrophy (DMD). A study published in the journal Molecular Therapy demonstrates that the experimental drug Setanaxib preserves cardiac function and reduces tissue scarring in preclinical models of the disease by inhibiting the NOX4 enzyme.
The Mechanical Toll of Dystrophin Deficiency
Duchenne muscular dystrophy is a progressive genetic condition caused by mutations that prevent the production of dystrophin, a protein essential for stabilizing muscle cells. Over time, these cells die and are replaced by fat and fibrotic scar tissue, leading to cardiomyopathy and eventual heart failure.
Targeting the NOX4 Enzyme
The USF Health team, led by Dr. Da-Zhi Wang, director of the Center for Regenerative Medicine at the USF Health Heart Institute, focused on the enzyme NOX4. At elevated levels, NOX4 produces reactive oxygen species that drive inflammation and fibrosis. By targeting this pathway, researchers aimed to slow the degradation of heart muscle.
Setanaxib and Cardiac Recovery
In the study, researchers evaluated the efficacy of Setanaxib, an experimental drug previously investigated in clinical trials for liver, kidney, and lung fibrosis. The findings indicate that the drug effectively limits the oxidative stress that contributes to DMD-related heart damage. According to the research team, including USF Health’s Dr. John Mably and Dr. Gabriela Diniz, treatment with Setanaxib resulted in:
- Preservation of the heart’s ability to pump blood.
- A reduction in cardiac tissue scarring (fibrosis).
- Limited heart enlargement.
- Decreased activity of genes associated with cardiomyopathy.
Bridging the Gap to Human Trials
Dr. Wang emphasized that understanding the biological mechanisms of DMD progression remains an urgent priority for improving patient quality of life.
A Streamlined Path for Translational Research
The work builds upon more than 15 years of investigation into the biological progression of muscular dystrophy conducted at the Wang laboratory.
>
Keep reading